By connecting metabolic and epigenetic changes, SET domain-containing 2 (SETD2), a histone lysine methyltransferase, integrates enhancer of zeste homolog 2 (EZH2) and the AMPK signaling pathway to limit prostate cancer spread [90]. Here, EZH2 is linked to prostate cancer.